Literature DB >> 19698279

Hemodynamic resuscitation in septic shock: cardiovascular support and adjunctive therapy.

Brian M Fuller1, R Phillip Dellinger.   

Abstract

Sepsis is associated with hemodynamic derangements that lead to tissue hypoperfusion and multisystem organ failure if uncorrected. Considerable data published in recent years have addressed detection and treatment of sepsis. However, much is unknown about the selection and titration of appropriate therapy, appropriate goals and end points for resuscitation, and the hemodynamic monitoring necessary based on these goals and end points. Current therapeutic interventions include preload optimization, initiation of timely and appropriate vasopressor and inotropic support, decisions about corticosteroid therapy and recombinant human activated protein C, and early and adequate antibiotic therapy. This article focuses on the cardiovascular support of the septic shock patient, and the current evidence to guide decisions on the use of corticosteroid therapy and recombinant human activated protein C.

Entities:  

Year:  2009        PMID: 19698279     DOI: 10.1007/s11908-009-0051-1

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  55 in total

1.  Measurements of right ventricular volumes during fluid challenge.

Authors:  C Reuse; J L Vincent; M R Pinsky
Journal:  Chest       Date:  1990-12       Impact factor: 9.410

2.  Using transcutaneous oxygen pressure measurements as selection criteria for activated protein C use.

Authors:  Alyssa D Chapital; Mihae Yu; Hao Chih Ho; John Wang; Wega Koss; Danny M Takanishi
Journal:  J Trauma       Date:  2008-07

3.  Passive leg raising predicts fluid responsiveness in the critically ill.

Authors:  Xavier Monnet; Mario Rienzo; David Osman; Nadia Anguel; Christian Richard; Michael R Pinsky; Jean-Louis Teboul
Journal:  Crit Care Med       Date:  2006-05       Impact factor: 7.598

4.  Pulmonary artery occlusion pressure and central venous pressure fail to predict ventricular filling volume, cardiac performance, or the response to volume infusion in normal subjects.

Authors:  Anand Kumar; Ramon Anel; Eugene Bunnell; Kalim Habet; Sergio Zanotti; Stephanie Marshall; Alex Neumann; Amjad Ali; Mary Cheang; Clifford Kavinsky; Joseph E Parrillo
Journal:  Crit Care Med       Date:  2004-03       Impact factor: 7.598

5.  Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial.

Authors:  Djillali Annane; Philippe Vignon; Alain Renault; Pierre-Edouard Bollaert; Claire Charpentier; Claude Martin; Gilles Troché; Jean-Damien Ricard; Gérard Nitenberg; Laurent Papazian; Elie Azoulay; Eric Bellissant
Journal:  Lancet       Date:  2007-08-25       Impact factor: 79.321

6.  Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Authors:  E Wesley Ely; Pierre-François Laterre; Derek C Angus; Jeffrey D Helterbrand; Howard Levy; Jean-François Dhainaut; Jean-Louis Vincent; William L Macias; Gordon R Bernard
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

7.  Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Authors:  Marcel Levi; Mitchell Levy; Mark D Williams; Ivor Douglas; Antonio Artigas; Massimo Antonelli; Duncan Wyncoll; Jonathan Janes; Frank V Booth; Dazhe Wang; David P Sundin; William L Macias
Journal:  Am J Respir Crit Care Med       Date:  2007-06-07       Impact factor: 21.405

8.  Vasopressin versus norepinephrine infusion in patients with septic shock.

Authors:  James A Russell; Keith R Walley; Joel Singer; Anthony C Gordon; Paul C Hébert; D James Cooper; Cheryl L Holmes; Sangeeta Mehta; John T Granton; Michelle M Storms; Deborah J Cook; Jeffrey J Presneill; Dieter Ayers
Journal:  N Engl J Med       Date:  2008-02-28       Impact factor: 91.245

9.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

10.  Benefits and risks of tight glucose control in critically ill adults: a meta-analysis.

Authors:  Renda Soylemez Wiener; Daniel C Wiener; Robin J Larson
Journal:  JAMA       Date:  2008-08-27       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.